{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T10:01:14Z","timestamp":1751796074441,"version":"3.40.4"},"reference-count":6,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2018,1,10]]},"abstract":"<jats:p>A 65-year-old woman with a 35-year history of limited cutaneous systemic scleroderma was admitted to our hospital complaining of a 3-month history of progressive dyspnoea on exertion. High-resolution CT images of the chest revealed diffuse reticular opacities and traction bronchiectasis predominantly in the bilateral lower lobes of the lung. Specimens obtained during video-assisted thoracic surgery were consistent with fibrocellular non-specific interstitial pneumonia and accompanied by accumulation of lymph follicles within areas of fibrosis. Although the patient received combination therapy with prednisolone and intravenous cyclophosphamide at a dosage of 500\u2009mg\/m<jats:sup>2<\/jats:sup>monthly for 5 months, her clinical condition deteriorated gradually. In addition, right heart catheterisation revealed borderline pulmonary arterial hypertension with mean pulmonary artery pressure of 24\u2009mm Hg. Therefore, we initiated a combination therapy of an antifibrotic agent, pirfenidone for 12 months, and the dual endothelin receptor antagonist, macitentan, with prednisolone. As a result, her clinical condition improved dramatically.<\/jats:p>","DOI":"10.1136\/bcr-2017-221755","type":"journal-article","created":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T12:29:09Z","timestamp":1527337749000},"page":"bcr-2017-221755","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic scleroderma-related interstitial pneumonia associated with borderline pulmonary arterial hypertension"],"prefix":"10.1136","volume":"2018","author":[{"given":"Keishi","family":"Sugino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Kabuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutoshi","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakae","family":"Homma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,5,26]]},"reference":[{"key":"2025042703430741000_2018.may25_1.bcr-2017-221755.1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151322"},{"key":"2025042703430741000_2018.may25_1.bcr-2017-221755.2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0649-7"},{"key":"2025042703430741000_2018.may25_1.bcr-2017-221755.3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200904-0563OC"},{"key":"2025042703430741000_2018.may25_1.bcr-2017-221755.4","first-page":"235","article-title":"Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease","volume":"31","author":"Miura","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025042703430741000_2018.may25_1.bcr-2017-221755.5","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004113","article-title":"A case report: the efficacy of pirfenidone in a Chinese patient with progressive systemic sclerosis-associated interstitial lung disease: a CARE-compliant article","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine"},{"key":"2025042703430741000_2018.may25_1.bcr-2017-221755.6","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease: scleroderma lung study II (SLS-II), a double-blind, parallel group, randomized controlled trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-221755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T10:43:14Z","timestamp":1745750594000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-221755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,26]]},"references-count":6,"alternative-id":["10.1136\/bcr-2017-221755"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-221755","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2018,5,26]]}}}